Ginkgo Bioworks DNA Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's accrued expenses and other liabilities?
- Ginkgo Bioworks (DNA) reported accrued expenses and other liabilities of $48.38M in Q1 2026.
- How has Ginkgo Bioworks's accrued expenses and other liabilities changed year-over-year?
- Ginkgo Bioworks's accrued expenses and other liabilities decreased by 31.6% year-over-year, from $70.75M to $48.38M.
- What is the long-term trend for Ginkgo Bioworks's accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Ginkgo Bioworks's accrued expenses and other liabilities has grown at a 16.9% compound annual growth rate (CAGR), from $30.51M to $66.46M.